ImmunityBio, Inc. (IBRX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $8.13. The rating moved from Oversold to Overbought on August 8, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$8.13
• Last changeMoved from Oversold to Overbought on August 8, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

ImmunityBio, Inc. (IBRX) is a clinical-stage immunotherapy/biologics company whose near-term value is tightly linked to clinical readouts, regulatory progress and partnership or financing activity. Sector-level tailwinds for biologics and elevated M&A multiples provide potential upside, but the company remains execution- and capital-sensitive; limited publicly available filings and social sentiment in the provided window increase reliance on event-driven catalysts. Given balanced market risk appetite and the binary nature of clinical outcomes, outcomes over the next month will likely be driven by any trial updates, financing news or strategic partnerships.

Key factors

• Clinical-stage focus on immunotherapies and biologics gives meaningful upside tied to trial readouts and regulatory milestones
• Sector tailwinds for biologics, CROs and CDMO demand could indirectly benefit program execution and partnership interest
• Elevated M&A multiples in biotech increase strategic attractiveness to larger pharma acquirers
• Market-wide risk appetite is balanced, leaving room for selective interest in growth/biotech stories without broad momentum
• Limited real-time social sentiment and no recent EDGAR comparison in the provided window increases reliance on event-driven catalysts
• Execution-sensitive business model: clinical data, manufacturing readiness and partnership deals will drive near-term valuation

Risks

• Clinical trial failure or delayed readouts that significantly reduce expected value of pipeline assets
• Cash burn and financing/dilution risk if capital markets are unfavorable or if operational costs accelerate
• Regulatory setbacks or protracted review timelines that delay commercialization paths
• Competitive landscape with larger, better-capitalized immunotherapy and biologics developers
• Manufacturing, supply-chain or CRO/CDMO capacity constraints that could delay studies or increase costs
• Low liquidity and stock volatility common to small/clinical-stage biotech, amplifying downside on negative news
• Lack of clear short-term catalysts in the provided market window increases uncertainty on price direction

Latest MarketMoodz coverage

• Cramer Backs CAVA in Mad Money Lightning Round2026-06-16
• ImmunityBio Gains FDA Acceptance for Expanded ANKTIVA Use2026-05-20
• FDA Flags Anktiva Claims as ImmunityBio Pushes Regulatory Fixes2026-04-06
• NCCN Expands Anktiva Guideline for Papillary NMIBC; ImmunityBio Stock Rises2026-03-17
• ImmunityBio Resubmits ANKTIVA for Expanded NMIBC Use2026-03-09

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.